For the year ending 2025-12-31, IPSC had $3,798K increase in cash & cash equivalents over the period. -$104,724K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -9,580 |
| Depreciation | 13,101 |
| Non-cash operating lease expense (benefit) | 1,912 |
| Stock based compensation | 6,840 |
| Impairment | 6,763 |
| Accretion of investments | 2,357 |
| Change in fair value of contingent liabilities | 4,534 |
| Gain on reduction in lease liability due to lease termination | 1,395 |
| Deferred tax (benefit) expense | -73 |
| Prepaid expenses and other assets | -2,342 |
| Operating lease liability | -4,978 |
| Deferred revenue | -109,164 |
| Accounts payable | 1,562 |
| Accrued expenses and other liabilities | -4,315 |
| Net cash used in operating activities | -103,876 |
| Acquisition of property and equipment | 848 |
| Acquisition of fixed maturity securities, available for sale | 51,174 |
| Sale of fixed maturity securities, available for sale | 159,523 |
| Net cash provided by investing activities | 107,501 |
| Proceeds from issuance of common stock and espp | 173 |
| Net cash provided by financing activities | 173 |
| Net increase in cash, cash equivalents, and restricted cash | 3,798 |
| Cash, cash equivalents and restricted cash, beginning of period | 61,213 |
| Cash, cash equivalents and restricted cash, end of period | 65,011 |
Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc. (IPSC)